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By exposing frozen sections of human skin to fresh 
normal human serum, binding and activation of comple-
ment was observed. Attached complement components 
Clq, C4, and C3 were detected by immunofluorescence 
microscopy using anticomplement conjugates. Isolated 
Clq bound to the same structures as serum Clq, C4, and 
C3 and binding of C4 and C3 was dependent on binding 
of Clq. The complement components bound to capillary 
endothelial cells and to fibrillar structures in the dermis 
and reacted with the epidermis. Complement binding 
dermal fibrillar structures in adult skin were scant but 
abundant in fetal skin. They had similar distribution as 
"microfibrils" demonstrable by human autoantibodies. 
Antibody independence of the Clq binding was shown 
using isolated Clq and by the observed constant and 
reproducible binding of complement of normal sera lack-
ing antibodies to the described target structures. The 
observations suggest that antibody independent binding 
of complement should be considered as a possible mech-
anism leading to dermal complement deposition in vivo. 
Deposits of complement components in the skin are fre-
quently demonstrated in various dermatological disorders [1). 
The concomitant deposition of immunoglobulins and comple-
ment suggests classical pathway activation initiated by local 
immune reactions or deposition of circulating immune com-
plexes [2]. In the absence of immunoglobulin, complement 
deposition is usually considered to be the result of alternative 
complement pathway activation of C3 [1, 3] but antib~dy­
independent classicial pathway complement activation should 
also be considered as this mechanism has been shown to be 
triggered by virus infected cells [ 4] and by tissue components 
[5, 6]. We have observed that cytoskeletal intermediate flla-
ments (IMF) of cultured cells [7] can cause complement acti-
vation in vitro through direct, antibody independent interaction 
with Clq. Intermediate filaments are cytoplasmic elements with 
an apparent cytoskeletal functio11 which are present in both 
cultured epithelial and mesenchymal cells [8]. The distribution 
of these filaments is incompletely known at the tissue level but 
vascUlar endothelial cells have recently been shown to contain 
abundant intermediate filaments capable of complement acti-
vation [9). 
This paper describes experiments in which the possibility of 
antibody independent mechanisms for complement deposition 
to skin was investigated. Frozen sections of adult and fetal 
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human skin and normal human serum or purified Clq were 
employed and bound complement components visualized by 
immunofluorescence microscopy. 
MATERIALS AND METHODS 
Tissues 
A total of 6 samples of adult normal human thoracic and abdominal 
skin was obtained in association with surgical procedures. Human fetal 
skin was obtained at 12 legal abortions performed during the ftrst 
trimester of pregnancy. The tissues were mounted in Tissue-Tek IT 
OCT compound (LabTek Products, Miles Laboratories, Naperville ill.), 
frozen in liquid nitrogen and 5 p.m sections were cut in a cryostat. The 
frozen sections were fixed similarly as cultured cells previously used in 
complement binding experiments (7, 9]: Fixation in 3.5% paraformal-
dehyde for 6 min was followed by treatment with a 0.1% solution of the 
detergent NP 40 (BDH, Poole, England) for 15 min. In control experi-
ments both paraformaldehyde fixation and the detergent treatment 
were omitted and complement binding experiments were performed 
using unfixed frozen sections immediately after thawing. 
Normal Human Sera 
Sera from 30 healthy blood donors of different blood groups were 
made available by the Finnish Red Cross Blood Transfusion Service. 
Immunofluorescence Microscopy and Immunoglobulin Conjugates 
Tissue bound complement components were detected by incubation 
with FITC anti-Ciq, F / P 2,2; FITC anti-C4, F / P 2,3; and FITC anti-
C3c, F / P 2,2 or TRITC anti-C3c (Behringwerke AG, Marburg, GFR). 
The dilutions were 1:20-1:80 and protein content of working solutions 
20-50 p.g/ml. The anti-immunoglobulin conjugates FITC anti-IGg F/ P; 
3,7, FITC anti-IgA F/P; 30, FITC anti-IgM F/P 4,9 were from Meloy 
Laboratories Inc., Springfield, Va. Anti-IgG TRITC conjugates were 
from Behringwerke AG, Marburg, GFR, and Cappel Laboratories. The 
working dilutions were 1:40-1:80 and protein about 10 p.g/ ml. 
For immunofluorescence microscopy, a Zeiss Standard microscope 
was used equipped with an Osram HBO 50 W high pressure mercury 
lamp and a II FL epi-illuminator for FITC: excitation filter BP 550-
590, dicroic mirror FT 510, and emission ftlter 520; for TRITC: excita-
tion filter BP 546/ 10, dicroic mirror FT 580 and emission ftlter 590. 
Assay for complement binding: In the standard assay, binding of 
complement components Clq, C4, and C3 was demonstrated as de-
scribed previously [7, 9): The ftxed and detergent-treated fro'zen sec-
tions were washed in phosphate buffered saline pH 7.1 (PBS) for at 
least 15 min with 3 changes of buffer and then incubated with normal 
human serum diluted 1:10 if not otherwise stated. PBS was used as 
diluent. After incubation for 30 min at room temperature the section 
was washed and incubated for 30 min with anticomplement conjugates 
anti-Clq, anti-C4, and anti-C3 (see previous section) . Control experi-
ments were performed using unfixed frozen sections: The sections were 
used immediately after cutting and thawing and incubated with serum 
for various lengths of time. Inhibition of complement binding was 
performed using 10 mM EDTA, 10 mM EGTA, heat inactivation or 
absorption with aggregated IgG [10]. The 30 normal human sera 
employed in studies of complement binding were negative when tested 
for antinuclear antibodies (ANA) and smooth muscle antibodies (SMA) 
and showed no reaction when tested for antibodies against the epider-
mis by IFL [11]. Purified human Clq, free of contaminating serum 
proteins, was obtained as described previously [10). 
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Marhers for connective tissue components and intermediate fila-
ments: The dermal-epidermal basement zone was visualized using 
rabbit antibodies against ftbronectin [12, 13]. In addition an antiserum 
produced against crude skin collagen was used as a marker as described 
previously [12). Human auto-antibodies reacting with connective tissue 
microfibrils (anti-MF) of human fetal skin [14, 15] and against inter-
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mediate filamen ts (an ti-IMF) [16-18] were mostly of IgM class a nd 
included one IgM myeloma protein [19]. 
Markers for the epidermis and vascular endothelium: An experi-
mental rabbit antiserum produced against human keratin [20] was used 
as a marker for epidermal cells. Antibodies against clotting factor VIII 
(anti-factor VIII, Clottimmune) from Behringwerke AG, Marburg, 
GFR, were used as markers for endothelial cells [21]. 
RESULTS 
Binding of complement components Clq, C4, and C3 was 
observed to take place to frozen sections of human skin. The 
target structures were (1) stratum corneum, (2) vascular endo-
thelial cells, (3) microfibrils of fetal dermas and occasional 
subepidermal fibrillar structures of adult dermis. 
In adult skin, complement binding to vessels was a prominent 
feature (Fig 1). Capillaries appearing as clusters of cells could 
be identified by their positive staining reaction with antibodies 
against clotting factor VIII (Fig 2). In addition, staining of 
subepidermal fibrils which were apparently unrelated to vessels, 
was frequently observed (Fig 1). The binding of complement to 
stratum corneum was diffusely granular (Fig 1) . The anticom-
plement conjugates alone did not bind. The sera used in the 
test for complement binding were selected not to give autoan-
FIG 1. Antibody-independent binding of complement component C4 
to adult normal human skin . 3 sites of C4 binding can be recognized in 
(a): the epidermal layer (arrowheads), subepidermal fibrillar structm es 
(arrows), and dermal vessels (V) . Vessel seen in higher magnification 
in (b). 5J.L frozen sections were fixed in 3.5% para formaldehyde, rinsed 
in detegent solution and incubated with normal human serum dilu ted 
1:10. Immunofluorescence staining of bound C4 with FITC anti-C4. (a) 
X150 and (b) x300. 
ANTI-BODY-INDEPENDENT BINDING OF ClQ 117 
FIG 2. Double immunofluorescence staining of dermal capillary for 
bound complement C3 (a) and clotting factor VIII (b) which is used as 
an endothelial cell marker. The cells associated with strong comple-
ment-binding structures are identified by typical granular staining for 
clotting factor VIII . C3 localization as in text to Fig 1 but using FITC 
anti-C3. Incubation with an t iclotting factor VIII was fo llowed TRITC 
anti-rabbit lgG (reduced from X800). 
FIG 3. Double immunofluorescence staining for ant ibody i11depen-
dent complement binding and microfibrillru· antigen(s). Location of 
bound C3 to fetal skin (a) is similru· to the binding of human autoanti-
bodies against connective tissue micro fibrils (an ti-MF) (b). Frozen 
section incubated fu·st with normal human serum and then with anti-
MF. Bound C3 detected as in text to Fig 1; anti-MF binding using FITC 
anti-human IgM. (X400). 
tibody dependant reactions with fetal connective tissue micro-
fibrils or stratum corneum by immunofluorescence. 
In fetal skin the dermal structm es having affinity for comple-
ment consisted of a network of fine fibrils (Fig 3) which were 
nonbranching and had the same general orientation. Comple-
ment reacted with the same structUl·es as autoantibodies against 
microfibrils (Fig 3a and b). Some fibrils extended up to the 
dermal-epidermal junction and were closely associated with the 
basement zone visualized by double antibody staining for fibro-
nectin and bound complement (Fig 4). In fetal skin the vessels 
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FIG 4. Double immunofluorescence staining of fetal skin for comple-
ment binding structures and fibronectin. (a) Location of C3 to upper 
epidermis and to subepidermal fibrils. Note that some complement-
binding fibrils extend to the junctional area (arrows) . Incubation with 
normal human serum followed by TRITC anti-C3. (b) Location of 
fibronectin at the dermal-epidermal junction. (Upper epidermal fluo-
rescence is due to strong staining for C3 and insufficient barrier filters. ) 
FITC anti-fibronectin (reduced from x600) . 
FIG 5. Upper epidetmal fluorescence in fetal ~kin seen with anti-
keratin antibodies. Note absence of fluorescence in the basal layer 
(X400). 
gave a similar complement binding pattern as the surrounding 
connective tissue. The stratum corneum of the epidermal layer 
reacted with serum complement (Fig 4). The pattern produced 
by bound complement was similar to that produced by anti-
bodies against keratin (Fig 5). 
Complement components Clq, C4, and C3 all produced a 
similar staining reaction. No binding of C4 and C3 was seen in 
the presence of 10 mM EDT A and 10 mM EGT A, which, 
however, did not affect Clq binding. Heat inactivation of serum 
at 56°C for 60 min completely inhibited the staining reactions. 
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FIG 6. Binding of serum Clq to unfixed frozen section of fetal skin. 
(a) Serum incubation time 30 sec. Note presence of both epidermal 
staining and dermal microfibrillar localization of Clq. (b) Serum incu-
bation time 2 min: Note faint granular Clq localization in the dermis 
(arrows) but more intense epidermal staining as compared to (a) . 
Bound Clq was identified using FITC anti-Clq (reduced from x500). 
The complement binding reaction was also completely abol-
ished by 10 J-f.g/ ml aggregated IgG added to normal serum. 
There was no demonstrable binding of immunoglobulins lgG, 
IgA, or IgM. Isolated Clq bound to the same target structures 
as Clq of whole serum. Identical complement binding patterns 
and similar intensity of fluorescence was seen with 30 individual 
normal human sera. Bound Clq was seen using serum dilutions 
of 1:40, C4, and C3 could be demonstrated in serum dilution 1: 
80-1:160. Some autofluorescence of. dermal connective tissue 
collagen and elastin fibers occurred but it did not intelfere with 
the interpretation of the specific binding reactions. No autoflu-
orescence was seen in fetal skin. 
Complement binding using unfixed frozen sections of shin. 
In unfixed frozen sections of adult and fetal skin only epidermal 
binding of the serum complement components occurred and no 
dermal fibrillar staining was observed in fetal skin (Fig 6). This 
appeared to be due to the destruction or solubilization of the 
target structures during the standard incubation procedure. 
The problem was overcome by using a short serum incubation 
time: Frozen sections of fetal skin were incubated for 10 sec, 30 
sec, 2 min, 10 min and 30 min with normal serum or serum 
containing 10 mM EDTA. Sections incubated with serum for 10 
and 30 sec showed the "microfibrillar" staining for Clq (Fig 6a). 
In sections incubated for 2 min the staining was less intense 
and appeared granular (Fig 6b). After the short incubation 
times virtually no binding of C4 or C3 was observed. This was 
consistent with the kinetics of complement binding fo fixed 
tissue. Presence of 10 mM EDT A or EGT A did not significantly 
inhibit the observed incubation-time-dependent disintergration 
of the "micro fibrils" of fetal dermis. 
Binding of isolated Clq to frozen sections of shin. Equivalent 
amounts of isolated Clq and serum Clq (quantitation by radial 
immunodiffusion) were used in complement binding experi-
ments. Isolated Clq in concentrations of 10 J-f.g/ml repeatedly 
gave a binding pattern indistinguishable from that of serum 
diluted 1:10 when stained for bound Clq with FITC anti-Clq: 
Binding of Clq occurred to stratum corneum and vessels of both 
fetal and adult skin and to the "microfibrils" of fetal dermis. 
DISCUSSION 
Immunofluorescence microscopy (IF) has been successfully 
employed for localization of antigens in tissues and for demon-
stration of antibody-antigen interactions in situations where 
the target antigen is difficult to isolate or even unknown. The 
approach of using IF in studies of complement interactions with 
tissue components is based on the same premises as the studies 
of antibody-antigen interactions by this method. We have pre-
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viously shown binding of Clq to native DNA [10] and binding 
of complement components to intermediate fllaments [7] by IF. 
The IF method has been used also for demonstration of in 
vitro, complement binding, eg., to cell surfaces [22] and frozen 
sections [23]. The obvious advantage of IF as compared to 
hemolytic techniques is that binding of individual complement 
components can be easily demonstrated and that target struc-
tures do not need to be isolated and thereby subjected to 
various potentially denaturing conditions. 
The following discussion will focus on 2 major points: First, 
the nature of the complement binding phenomenon. Secondly, 
identification of the tissue components having the capacity to 
bind complement. The results showed strong binding of com-
plement components Clq, C4, and C3 to dermal structures. No 
binding of antibodies which might have been responsible for 
fixing Clq could be demonstrated. However, it is not sufficient 
to exclude antibody dependence of the observed complement 
binding. It could be ru·gued that the ratio of bound immuno-
globulin to bound complement is low which accounts for detec-
tion of only the later acting complement components. This is 
particularly important as antistratum corneum antibodies are 
commonly observed in normal human sera (11, 23). Such a 
phenomenon was described in herpes gestationis (23-25) where 
a complement fixing IgG class autoantibody against the base-
ment membrane zone may be present in such small quantities 
as to escape detection by the indirect IF assay. Failure to 
demonstrate the autoantibody may be due to its presence in 
very low concentration but complement deposition in this con-
dition might be dependent also upon other factors as presence 
of autoantibody does not correlate to the clinical expression of 
the disease [26]. Complement activating autoantibodies in small 
quantities can explain visible C3 deposition by amplification 
through self perpetuating "loop activation" [3], however, pu-
tative autoantibodies ru·e not likely to explain the observed 
strong binding of Clq observed in this study as no ampliciation 
occurs at this step [2]. It is also difficult to imagine presence of 
autoantibodies against epidermis, endothelia and microfibrils 
occurring in constant amounts in all 30 normal sera tested . 
Finally, Clq free from demonstrable serum contruninants, in-
cluding immunoglobulins, exhibited similar binding in analo-
gous concentrations as serum Clq. No evidence for direct, 
alternative pathway binding of C3 was seen; C3 binding was 
shown to be dependent on presence of both Mg2+ and 
Ca2+, which indicates classical complement pathway activation 
[2, 3]. The results strongly suggest that Clq binds directly to 
tissue components without participation of antibodies and that 
this binding causes classical pathway complement activation. 
Obviously the experimental set up of the complement binding 
experiments may introduce in vitro, rutifacts. The question is 
how well the experimental conditions reflect changes which 
may occur in vivo. The frozen sections used in this study can 
be regarded as tissue altered in vitro in a way not likely to occur 
in vivo. One may however argue that frozen sections are ac-
ceptable in vitro models for an in vivo altered tissue and that 
the denaturation involved in the described procedure is rela-
tively mild. The demonstration of rapid and specific binding of 
Clq not only to fixed tissue but also to frozen sections which 
had not been denatmed by fixation or detergent treatment 
therefore suggests that the observed antibody-independent 
complement binding may be a relevant model for complement 
deposition in vivo. 
The target structmes responsible for binding and activation 
of Clq were partly chru·acterized. Binding of complement to 
vascular endothelium especially in dermal capillru·ies could 
easily be recognized. This phenomenon has been studied in 
detail using vessels of placental villi [9] and renal t issue [9, 27] 
as substrates. Cytoplasmic intermediate fJ.laments of cultmed 
endothelial cells are complement binding [28] similarly to flla-
ments of other cultmed cells [7]. The epidermal structures 
capable of binding complement have so far not been identified. 
However, they might be associated with intermediate filaments 
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of vimentin type which have been described also in cultured 
cells of epithelial origin [8,20,29]. Also the nature of the sub-
epidermal complement binding fibrillru· structures remains un-
known. Possibly they develop from the dermal fibrils in fetal 
skin shown to be capable of binding complement. The latter 
fibrils could be identified as connective tissue "microfibrils" are 
appru·ently at least pru·tly extracellular as they are associated 
with filamentous fibronectin [17] and with amorphous elastin 
demonstrable histologically [14,30]. It is an interesting possibil-
ity that the "microfibrils" may be related to the epidermis-
anchoring system of adult skin [30,31]. The observations suggest 
that complement may be activated by dermal and epidermal 
structures independently of antibodies and that this should be 
considered as a possible pathogenetic mechanism in vivo. 
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Announcement 
In 1982, the Certify ing Examina tion of the American BoaTd of D erma tology will be held on Octo ber 24 
and 25 in Chicago, Illinois. The deadline for receipt of applications is May 1, 1982. The D ermatopathology 
special competence examination will be held in San Diego, California on November 20, 1982. For further 
information on eith er of these examinations, please contact: Clarence S. Livingood, M .D., Execut ive 
Drrector, American Board of Dermatology, H enry Ford Hospital, Detroit, MI 48202. 
